Trial Profile
A study compared the effects of 2 doses Treprostinil in the patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who could not have surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 03 Oct 2018 New trial record
- 05 Sep 2018 According to a European Medicines Agency media release, the marketing authorisation application (MAA) of intravenous treprostinil for the treatment of pulmonary hypertension was withdrawn by SciPharm Sarl from the Committee for Medicinal Products for Human Use (CHMP). This application was based on this trial.